TG Therapeutics Inc (TGTX) SMASHES Q3 Revenue Expectations: What’s Driving Their Success?
TG Therapeutics Inc (TGTX) has just released their financial results for the third quarter ending September 30, 2023, and the numbers are nothing short of astonishing. With a total net revenue of $165.8 million, including a whopping $140.0 million license revenue from Neuraxpharm and $25.1 million in U.S. BRIUMVI® net sales, TGTX is making waves … Read more